Beinaglutide
Sources
registry, as of 2023-03-17Stale
https://clinicaltrials.gov/study/NCT05005741
The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.. Overall status UNKNOWN. Phases PHASE4. Lead sponsor Second Xiangya Hospital of Central South University. Enrollment 120. Conditions Diabetes Mellitus, Type 2; Overweight or Obesity. This study is a multi-center, open label, randomized controlled trial that main purpose of this study is to evaluate the differences of glucose control and weight loss between Beinaglutide and Dulaglutide in type 2 diabetes with overweight or or Obesity.
ClinicalTrials.gov NCT05005741 protocol and results modules
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT05005741
trial to investigate the differences of glucose control and weight loss between two GLP-1 receptor agonist, Beinaglutide and Dulaglutide, in type 2 diabetes with overweight or Obesity. The study comprises the 0-2 weeks of screening period and the 16-week intervention period. 120 patients according to the inclusion/
NCT05005741 description or intervention text